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The major α1,3fucosyltransferase activity in plasma, liver,
and kidney is related to fucosyltransferase VI which is
encoded by the FUT6 gene. Here we demonstrate the pres-
ence of α1,3fucosyltransferase VI (α3-FucT VI) in the
human HepG2 hepatoma cell line by specific activity
assays, detection of transcripts, and the use of specific anti-
bodies. First, FucT activity in HepG2 cell lysates was shown
to prefer sialyl-N-acetyllactosamine as acceptor substrate
indicating expression of α3-FucT VI. RT-PCR analysis fur-
ther confirmed the exclusive presence of the α3-FucT VI
transcripts among the five human α3-FucTs cloned to date.
α3-FucT VI was colocalized with β1,4galactosyltransferase
I (β4-GalT I) to the Golgi apparatus by dual confocal
immunostaining. Pulse/chase analysis of metabolically
labeled α3-FucT VI showed maturation of α3-FucT VI
from the early 43 kDa form to the mature, endoglycosidase
H-resistant form of 47 kDa which was detected after 2 h of
chase. α3-FucT VI was released to the medium and
accounted for 50% of overall cell-associated and released
enzyme activity. Release occurred by proteolytical cleavage
which produced a soluble form of 43 kDa. Monensin treat-
ment segregated α3-FucT VI from the Golgi apparatus to
swollen peripheral vesicles where it was colocalized with
β4-GalT I while α2,6(N)sialyltransferase remained associ-
ated with the Golgi apparatus. Both constitutive secretion
of α3-FucT VI and its monensin-induced relocation to ves-
icles analogous to β4-GalT I suggest a similar post-Golgi
pathway of both α3-FucT VI and β4-GalT I.
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Introduction
The α1,3fucosyltransferase (α3-FucT) enzyme activity has
been detected in various types of tissues (Mollicone  et al.,
1990, 1992; for review, see Macher  et al., 1991). FucTs con-
stitute a family of homologous glycosyltransferases with a
high degree of identity (Lowe, 1991). This family comprises
five different fucosyltransferases, named α3-FucT III to VII
(Goelz  et al., 1990; Kukowska-Latallo  et al., 1990; Koszdin
and Bowen, 1992; Weston  et al., 1992a,b; Sasaki  et al., 1993;
Natsuka  et al., 1994). These enzymes differ in their capacity to
transfer fucose to distinct oligosaccharide acceptors, cation
requirements and tissue specific expression (Goelz  et al.,
1990; Kukowska-Latallo  et al., 1990; Mollicone  et al., 1990,
1992; Lowe, 1991; Macher  et al., 1991; Weston  et al.,
1992a,b; Koszdin and Bowen, 1992, Sasaki  et al., 1993; Nat-
suka  et al., 1994). The five FucTs can be divided in two main
subgroups, one comprising α3-FucTIV and VII, the other α3-
FucTIII, V, and VI which are encoded by syntenically
arranged genes. These are identical to 85% rendering their spe-
cific detection by molecular probes or immunological reagents
difficult.
While the respective functions of α3-FucTIV and VII are
being increasingly understood on the basis of their specific
deletion in mice rendering them unable to synthesize selectin
ligands (Lowe, 1997), the function of the three remaining
FucTs needs to be further investigated. The study of develop-
mental changes of tissue specific expression and the conse-
quences of genetic polymorphisms all constitute approaches
towards this goal (Mollicone  et al., 1994). For instance the
FUT5 and FUT6 genes, respectively, encode two different
enzymes with activities exhibiting the specificity of the plasma
α1,3fucosyltransferases (Koszdin and Bowen, 1992; Weston
et al., 1992a). In several Java families the plasma
α1,3fucosyltransferase activity has been found to be deficient.
This deficiency was a result of a mutation in the FUT6 gene
(Mollicone  et al., 1994). The linkage relationship between a
α3-FucT VI mutation and deficiency of plasma fucosyltrans-
ferase activity was further confirmed by work of van Dijk and
associates (Brinkman-Van der Linden  et al., 1996): The mis-
sense mutation in the α3-FucT VI gene led to a complete
absence of α3-fucosylation of serum glycoproteins. In sera of
different individuals with inactivated FUT6 gene but with a
functional FUT5 gene α1,3fucosyltransferase activity has not
been detected (Brinkman-Van der Linden  et al., 1996). This
finding excluded the involvement of FUT5 in contributing to
plasma FucT activity. While it seems clear that the FUT6 gene
encodes the plasma α1,3fucosyltransferase activity, its tissue
origin has not formally been identified. Kidney is one candi-
date source of α3-FucT VI as a plasma fucosyltransferase
activity. In the case of an α3-fucosylated individual with a con-
genital kidney anomaly, only 10% of FucT plasma activity has
been detected which could be ascribed to the myeloid type
(Caillard  et al., l988). Lack of expression of the Lex
 antigen in
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Borsig et al.the kidney of this individual suggested that this organ may
normally contribute to plasma FucT activity (Caillard  et al.,
l988; Mollicone  et al., 1990). Another candidate for the origin
of a plasma FucT activity is the liver, where transcripts of α3-
FucT VI and enzyme activity corresponding to α3-FucT VI
have been detected (Mollicone  et al., 1990, 1992; Johnson  et
al., 1995). This organ is the source of many plasma proteins. In
addition, another glycosyltransferase, e.g. β1,4galacto-
syltransferase found in human serum originates at least par-
tially from liver (Kim  et al., 1972a,b).
While α3-FucT V and α3-FucT VI were investigated as
recombinant enzymes expressed in CHO cells (Borsig  et al.,
1996, 1998) little is known on localization, intracellular trans-
port, and release of endogenously expressed fucosyltrans-
ferases. Since the major α1,3fucosyltransferase activity in
human plasma is encoded by α3-FucT VI and putatively
released from the liver, we examined whether the HepG2
hepatoma cell line expresses α3-FucT VI and investigated
localization, biosynthesis, intracellular transport, and release
of this enzyme in these cells. In addition, β4-GalT I and α3-
FucT VI were found to react similarly to monensin treatment
which may indicate an analogous post-Golgi pathway (for
review, see Dinter and Berger, 1998).
Results
Fucosyltransferase activity in HepG2 cells
Lack of fucosylation of liver-derived serum glycoproteins in
patients affected by a deficiency of α3-FucT VI (Brinkman-
Van der Linden  et al., 1996) prompted us to investigate α3-
FucT activity in lysates of HepG2 cells, an established liver
carcinoma cell line. To determine the nature of the α1,3fuco-
syltransferase activity detected in HepG2 cells we used the
acceptor substrates listed on Table II. Acceptor substrate pref-
erence of the overall fucosyltransferase activity was directed
toward type 2 acceptors, N-acetyllactosamine (LacNAc), and
its sialylated derivative 3’-sialyllactosamine (sLacNAc). In
addition, type 1 acceptor lacto-N-biose as well as type 6 accep-
tor 2’-fucosyllactose were poorly utilized (The definition of
acceptor types are as follows: type 1: Galβ1→3GlcNAc; type
2: Galβ1→GlcNAc; type 6: Galβ1→4Glc). The very low ratio
of utilization of type 1 to type 2 acceptors allowed to exclude
expression of FucTIII to a significant amount. Preference for
type 2 acceptor (neutral or sialylated) were in good agreement
with the previously reported results of FucT activity in human
liver cells (Jezequel-Cuer  et al., 1993) and in human serum
(Sarnesto  et al., 1992). The majority of the α3-FucT activity in
plasma is due to α3-FucT VI which is encoded by the FUT6
gene (Brinkman-Van der Linden  et al., 1996). Indeed, a very
similar acceptor specificity profile has been obtained with
cloned α3-FucT VI expressed in CHO (Borsig  et al., 1998),
COS cells (Koszdin and Bowen, 1992), or insect cells (De
Vries  et al., 1997). To assign HepG2 cell-associated α3-FucT
activity to α3-FucT VI or α3-FucT V, the enzyme activity of
α1,3fucosyltransferase from HepG2 cell lysates was subjected
to a neutralization experiment with a specific antiserum (desig-
nated OLI) raised against recombinant α3-FucT VI (Borsig  et
al., 1998) (Figure 1). The OLI antiserum was able to inhibit the
enzymatic activity with LacNAc and sLacNAc as respective
acceptors by at least 90%. The inhibition with antibodies was
similar with both acceptors suggesting the expression of either
α3-FucT VI or α3-FucT V.
α3-FucT VI is the only α1,3fucosyltransferase expressed in 
HepG2 cells
Since the OLI antiserum raised against α3-FucT VI also cross-
reacts with α3-FucT V and α3-FucT III (Borsig  et al., 1998),
further determination of the α3-FucT expressed in HepG2 cells
Fig. 1. Inhibition of α1,3fucosyltransferase activity in HepG2 cell lysates 
using the OLI antiserum. α3-FucT VI activity was assayed in lysates of HepG2 
cells as described in Materials and methods using LacNAc and sialyl-N-
acetyllactosamine as acceptors, respectively. 1, Control assay mixture of 50 µl 
supplemented with 20 µl of H2O. 2, As in 1, with 20 µl of preimmune serum 
(PIS). 3, As in 1, with 10 µl of PIS and 10 µl of OLI antiserum. 4, As in 1, with 
20 µl of OLI antiserum.
Table I. PCR primers for amplifying fucosyltransferases
aU, Upper strand primer; L, lower strand primer.
bNumbers in parentheses indicates fragment size in base pairs.
mRNA species 
detected
Primersa
3-FucT III(585)b U: 5’ACCACTGGGATATCATGTCCAACCCTAAGT3’
L: 5’GGGCCAGGTCCTTGGGGCTCTGGAAGTCG3’
α3-FucT IV(589) U: 5’GGGGCATCCAGGCGCACACTGC3’
L: 5’CGCTCGTAGTTGGCACGGTCTG3’
α3-FucT V(811) U: 5’CCAGGGCTTATGGCAGTGGAACCTGTCAC3’
L: 5’GGGCCAGGTCCTTGGGGCTCTGGAAGTCG3’
α3-FucT VI(737) U: 5’ATCCCACTGTGTACCCTAATGG3’
L: 5’CGGCAGGAACCTCTCGTAGTTG3’
α3-FucT VII(448) U: 5’CCTGGGTGGTCAGCAACTTC3’
L: 5’CGGTCACAGATGGCACAGAAAC3’1274
α3FucT VI expression in HepG2 cellswas done by RT-PCR analysis. Based on activity measure-
ments, α3-FucT VI and α3-FucT V could be expected. To be
able to distinguish between α3-FucT V and α3-FucT VI
expression, we used specific primers for α3-FucT V (Borsig  et
al., 1998) and α3-FucT VI (Table I). Absence of a signal in
controls and specific amplification from cDNA and genomic
DNA showed expression solely of α3-FucT VI in HepG2 cells
(Figure 2, lane 4). PCR amplification with α3-FucT V primers
yielded no product (Figure 2, lane 1). RT-PCR amplification
with specific primers for α3-FucT III were also negative (Fig-
ure 2, lane 17). Although crossreactivity of OLI antibodies
with α3-FucT IV and α3-FucT VII was not observed (data not
shown), RT-PCR analysis was carried out, also with negative
results (Figure 2, lanes 9, 13). Taken together, we conclude
that among the five cloned α3-FucTs α3-FucT VI only is
expressed in HepG2 cells.
α1,3Fucosyltransferase VI is localized to the Golgi apparatus
To determine the steady-state distribution of α1,3fuco-
syltransferases VI, HepG2 cells were subjected to indirect con-
focal immunofluorescence microscopy (Figure 3). For staining
of α3-FucT VI, previously characterized polyclonal affinity
purified OLI antibodies were used (Borsig  et al., 1998)
(Figure 3C). A specific Golgi staining was found using OLI
antibodies to α3-FucT VI (Figure 3C), while preimmune
serum (Figure 3A) or staining with antibodies preabsorbed
with rα3-FucT VI antigen (Figure 3B) produced background
staining only. Golgi location of FucT was further confirmed by
double confocal immunofluorescence staining with a mono-
clonal antibody to β1,4-galactosyltransferase I (Berger  et al.,
1986) indicating colocalization of both antigens (Figure 3C,D).
Maturation of α3-FucT VI in HepG2 cells and its release into 
the medium
To determine the molecular weight of α3-FucT VI expressed in
and released from HepG2 cells, immunoblotting of cell lysates
and supernatants with OLI antibodies was carried out (Figure 4).
In HepG2 cells, α3-FucT VI appeared as a 46.5 kDa protein,
thus slightly smaller than the recombinant enzyme in CHO cells
which was detected as a 47 kDa band (Borsig  et al., 1998). The
small difference might be due to cell-type-specific glyco-
sylation. The enzyme released from HepG2 cells migrated as a
45 kDa protein indicating an analogous processing step for the
endogenously expressed enzyme as for the recombinant enzyme
described previously (Borsig  et al., 1998; Grabenhorst  et al.,
1998). Fucosyltransferase activity was also measured in the
medium (Table II). The specificity of the released enzymatic
activity was similar to the intracellular enzyme. The cumula-
tive amount of enzyme released was half of total activity
recovered in the cell lysate and in the medium. Maturation of
α3-FucT VI in HepG2 cells was analyzed by metabolic labe-
ling followed by immunoprecipitation. HepG2 cells were sub-
jected to pulse-chase analysis (Figure 5). The 43 kDa form (no
chase), corresponding to the core glycosylated enzyme, par-
tially shifted to 46.5 kDa after 60 min, which became prepon-
derant after 2 h. The 43 kDa form was sensitive to endo-H
treatment (no chase) or PNGase treatment (not shown) and was
reduced to a 36.5 kDa form indicating that all four N-glyco-
sylation sites are occupied. After 2 h chase, endoglycosidase-H
treatment reduced the mature form to ~45 kDa (chase 120 min)
while converting the nonprocessed forms to 36.5 kDa. The
Table II. Measurement of Fuc-T activity in lysates of HepG2 cells and in the medium; comparison with recombinant α3-FucT 
VI activity from CHO cells
aA value of 100% was assigned to the specific activities generated by each enzyme with the acceptor N-acetyllactosamine. 
Relative activities for each of the other acceptors were then calculated by taking the ratio of their respective specific activities 
to the specific activity observed with N-acetyllactosamine;
bNot determined.
Acceptor activity of α1,3fucosyltransferase
Relative activitya (%) Activity (pmol/min/mg prot.)
rec. α3-FucT VI HepG2 lysate HepG2 medium Lysate Medium
N-Acetyllactosamine 100 100 100 95
Galβ1→4GlcNAc
Lacto-N-biose I 0.3 <0.1 — <0.1 ndb
Galβ1→3GlcNAc
2'-Fucosyllactose 4.5 3 — 3 nd Fucα1→2Galβ1→4Glc
3'-Sialyl-N-acetyllactosamine 131 110 117 105 2.3
NeuAcα2→3Galβ1→4GlcNAc
Fig. 2. RT-PCR of α1,3fucosyltransferases in HepG2 cells. After PCR analysis 
an aliquot was loaded on a 1.5% agarose gel containing ethidium bromide. α3-
FucT V: lanes 1–3, 7; α3-FucT VI: lanes 4–6, 8; α3-FucT IV: lanes 9–12; α3-
FucT VII: lane 13–16; α3-FucT III: 17–20; cDNA from HepG2 cells: lanes 1, 
4, 9, 13, 17; RNA controls: lanes 2, 5, 10, 14, 18; H2O controls: lanes 3, 6, 11, 
15, 19; genomic DNA: lanes 7, 8, 12, 16, 20.1275
Borsig et al.partial sensitivity to endoglycosidase most likely indicates that
not all of the four N-glycans are converted to complex type. In
summary, maturation of α3-FucT VI expressed in HepG2 cells
was almost identical to the one previously observed for rα3-
FucT VI expressed in CHO cells (Borsig  et al., 1998).
Colocalization of α3-FucT VI with β4-GalT I in monensin-
induced swollen vesicles
Previous data have shown that monensin, an established Golgi-
disturbing agent (for reviews, see Mollenhauer  et al., 1990;
Dinter and Berger, 1998), segregates β4-GalT I from sialyl-T
by relocating β4-GalT I to peripheral swollen vesicles (Berger
et al., 1993). While the nature of these vesicles has not been
unequivocally determined, they most probably belong to a
post-Golgi compartment. In support of this view, β4-GalT I
has been found to colocalize with TGN46 in monensin-
induced swollen vesicles (Figure 6G/H). Since TGN46 is a
well characterized marker of the TGN which recycles to the
cell surface within the post-Golgi compartments (for review,
see Banting and Ponnambalam, 1997) and which does not
colocalize with β4-GalT I under steady-state conditions (Pres-
cott  et al., 1997) the structures in which both TGN46 and β4-
GalT I colocalize (Figure 6 G/H) are compatible with Golgi-
derived vesicles. It was therefore of interest to investigate
whether α3-FucT VI would conform to the same segregative
behavior than β4-GalT I: HepG2 cells were treated with mon-
ensin for 30 min and analyzed by confocal immunofluores-
cence: As shown on Figure 6, α3-FucT VI (panel D)
colocalizes in swollen vesicles with β4-GalT I (panel C) in
monensin-treated cells, whereas ST6Gal I (panel B) and gian-
tin (panel A), a putative structural protein with predominant
cytoplasmic orientation (Linstedt and Hauri, 1993), remain
colocalized in a nondisturbed Golgi pattern. The difference
between the monensin effect on β4-GalT I and giantin is
shown on Figure 6, E and F, respectively. The monensin-
induced dissociation of β4-GalT I, α3-FucT VI, and TGN46
was completely reversible within 1 h after washing-out mon-
ensin (not shown). Thus, β4-GalT I and α3-FucT VI, both con-
stitutively secreted enzymes, reacted similarly to monensin
treatment but distinctly from ST6Gal I and giantin.
Discussion
In this work we present the first localization and trafficking
study of an endogenously expressed fucosyltransferase. More
specifically, this work deals with the presence and expression
of α3-FucT VI, the product of the FUT6 gene, in hepatocyte-
derived cells. Based on α1,3fucosyltransferase activity
Fig. 3. Localization of α3-FucT VI in HepG2 cells by confocal 
immunofluorescence microscopy. Cells were grown and subjected to 
immunofluorescence labeling using the OLI antiserum as described in 
Materials and methods. (A) HepG2 cells stained with OLI preimmune serum; 
(A1) corresponding interference contrast picture (Nomarski); (B) HepG2 cells 
stained with OLI antibodies preabsorbed with srα3-FucT VI; (B1) 
corresponding interference contrast picture (Nomarski); (C) and (D) HepG2 
cells double labeling for α3-FucT VI using affinity purified OLI antibodies 
(C) and β1,4-galactosyltransferase I using the mAB GT2/36/118 (D).  Scale 
bar, 10 µm.
Fig. 4. Immunoblotting of α3-FucT VI in lysates and supernatants of HepG2 
cells. HL, HepG2 cell lysate; CL control lysate from CHO cells stably 
transfected with α3-FucT VI (19); HS, HepG2 cell supernatant, see Materials 
and methods. PIS, OLI stained with OLI preimmune serum; IM, OLI stained 
with OLI immune serum.1276
α3FucT VI expression in HepG2 cellsmeasurements in human liver, α3-FucT VI was already
assumed to be expressed in liver cells (Mollicone  et al., 1990;
Johnson  et al., 1995). Previous work carried out by Johnson et
al. already surmised expression of α3-FucT VI in human liver
on the basis of activity measurements, immunochemical evi-
dence using an antibody crossreactive with α3-FucT III and
Northern analysis of human liver tissue and HepG2 cells. In
this work we confirm and extend these findings by RT-PCR
analysis of Hep-G2 cell mRNA showing the exclusive expres-
sion of α3-FucT VI among the five human α1,3fuco-
syltransferases cloned to date. Indeed, enzyme activity in
HepG2 cells measured with different acceptors showed a very
similar pattern of acceptor substrate preference as already
observed by the transient expression of α3-FucT VI in COS
cells (Koszdin and Bowen, 1992) and its stable expression in
CHO cells (Borsig  et al., 1998). However, enzyme activity
measurements could not unequivocally delineate the number
and nature of the possible α3-FucTs which are expressed in
HepG2 cells. In normal human liver, transcripts of α3-FucT V
as well as α3-FucT VI have been detected (Johnson  et al.,
1995). In the work of Mollicone and colleagues expression of
at least one α1,3fucosyltransferase enzyme in liver cells was
suggested (Mollicone  et al., 1990, 1992). To exclude expres-
sion in HepG2 cells of other members of the α3-FucT family,
RT-PCR analysis was carried out. After careful adjustment of
amplification conditions for each one of the cloned α3-FucTs
only the expression of α3-FucT VI could be documented (Fig-
ure 2). Using antibodies specifically recognizing α3-FucT VI
though crossreacting with α3-FucT III and V (Borsig  et al.,
1998) we identified a band by immunoblotting which likely
represents α3-FucT VI since the expression of both crossreac-
tive α3-FucT III and V has been excluded on the basis of RT-
PCR analysis. Moreover, α3-FucT V exceeds the size of α3-
FucT VI by 15 amino acids. Thus, crossreactive α3-FucT V
would migrate on SDS–PAGE differently from α3-FucT VI.
α3-FucT III could be excluded on the basis of acceptor specif-
icity: lacto-N-biose clearly was not a substrate (Table II) as
would be expected in the case of α3 FucT III expression
Fig. 5. Maturation of α3-FucT VI in HepG2 cells. HepG2 cells were pulsed for 
20 min and chased as indicated, immunoprecipitated, and treated with 
endoglycosidase H as indicated. Details are described in Materials and 
methods.
Fig. 6. Monensin selectively disturbs β4-GalT I/α3-FucT VI structural 
elements of the Golgi apparatus. HepG2 cells (A–F) and fibroblasts (G, H) 
were treated with 2 µM monensin for 30 min and processed for dual stain 
immunofluorescence confocal microscopy: (A/B) giantin/ST6Gal I; (C/D) β4-
GalT I/α3-FucT VI; (E/F) β4-GalT I/giantin; (G/H) β4-GalT I/TGN46. 
Elements where colocalization is easily apparent are marked with an arrow. 
Scale bar, 10 µm.1277
Borsig et al.(Johnson  et al., 1995). Here we also assign α3-FucT VI to the
list of late-acting Golgi-associated glycosyltransferases. Dou-
ble labeling with β4-GalT I, a trans Golgi enzyme (Slot and
Geuze, 1983), by using confocal microscopy, suggests colocal-
ization of both enzymes which would implicate a trans locali-
zation also for α3-FucT VI. Despite several efforts,
ultrastructural localization of this enzyme has not been possi-
ble. Circumstantial evidence suggested the presence of recom-
binant α3-FucT VI in distal Golgi compartments for its ability
to compete with an α2,3sialyltransferase (Grabenhorst  et al.,
1998).
The plasma α1,3fucosyltransferase activity is encoded by
the FUT6 gene (Mollicone  et al., 1994; Brinkman-Van der
Linden  et al., 1996). The origin of this activity remains
unknown. The liver has been suggested to be one of the poten-
tial candidate sources for the plasma activity (Mollicone  et al.,
1990, 1992; Johnson  et al., 1995). The observed release of the
α3-FucT VI enzyme activity from HepG2 cells provides the
first indication that the liver could be, at least in part, the source
of plasma α3-FucT activity. The 50% of FucT total activity
present in medium of HepG2 cells indicates efficient release
from the cells. By contrast, pulse-chase analysis showed a
rather slow maturation of α3-FucT VI, which reached a partial
endo-H resistance only after 2 h (Figure 5). Partial endo-H
resistance is a common feature for the α3-FucT VI enzyme
which was already observed in stably transfected CHO cells,
where even the secreted form did not reach full resistance
(Borsig  et al., 1998). Release of α3-FucT VI occurs upon pro-
teolytical cleavage accompanied by a reduction in molecular
mass of the enzyme. Observations with other glycosyltrans-
ferases indicated that release of soluble forms of enzymes
occurs by the action of serine-like (Strous and Berger, 1982;
Masri  et al., 1988; Homa  et al., 1993) and cathepsin-like pro-
teases (Weinstein  et al., 1987). The site of action of proteolytic
processing of released glycosyltransferase remains to be deter-
mined. In this regard, it is interesting to observe that the post-
Golgi fate of α3-FucT VI resembles in several aspects the fate
of β4-GalT I. This enzyme is also easily detectable as a soluble
glycosyltransferase in serum (Kim  et al., 1972a,b) and other
body fluids (Gerber  et al., 1979), is located to the trans side of
the Golgi apparatus (Roth and Berger, 1982; Slot and Geuze,
1983) and appears to share a common post-Golgi pathway with
α3-FucT VI as inferred by their dissociation from the Golgi
apparatus to Golgi-derived vesicles when cells are treated with
monensin (Dinter and Berger, 1998; Berger et al., unpublished
observations).
The nature of the swollen vesicles induced by monensin
treatment has not yet been unequivocally determined. Their
appearance and location as well as codistribution of TGN46
are compatible with the view that they are TGN-derived. A
number of other genuine Golgi proteins, such as ST6Gal I,
giantin (as shown on Figure 6), mannosidase II, N-
acetylgalactosaminyltransferase II and ST3Gal III (unpub-
lished observations) also remain associated with the Golgi
apparatus, indicating a specific post-Golgi behavior of β4-
GalT I and α3-FucT VI.
In summary, we show that HepG2 cells harbor and secrete
α3-FucT VI which is colocalized with β4-GalT I and which
shows a trafficking behavior analogous to β4-GalT I.
Materials and methods
Cell culture and RNA isolation
HepG2 cells were obtained from American Type Culture Col-
lection. They were grown in Dulbecco’s modified Eagle
medium (Gibco BRL) containing 10% fetal calf serum (com-
plete medium). Total RNA from 1 × 108 HepG2 cells was iso-
lated with guanidinium isothiocyanate followed by
centrifugation on cesium chloride cushions (Sambrook  et al.,
1989). The mRNA was isolated from the total RNA using
polyT-linked Dynalbeads (Dynal, Norway) according to the
manufacturer's protocol.
RT-PCR analysis of fucosyltransferases
First strand cDNA was prepared using 2 µg of poly(A)+ RNA.
Synthesis of cDNA was carried out with 200 U of M-MLV
reverse transcriptase (Gibco BRL) and 50 pmol of oligo dT
primer. For PCR of fucosyltransferases specific primers were
used as depicted in Table I. For α3-FucT III 30 cycles were
used as follows: 1 min 95°C, 1 min 63°C, 1 min 72°C; for
FucT IV 35 cycles were used as follows: 50 s at 95°C; 40 s at
60°C; 50 s at 72°C and final extension of 5 min. For α3-FucT
V and α3-FucT VI 35 cycles were used as described previously
(Cameron  et al., 1995). For α3-FucT VII 35 cycles were used
as follows: 50 s at 95°C; 40 s at 58°C; 48 s at 72°C and final
extension of 5 min. PCR amplifications with 10 ng of genomic
DNA for each FucT to prove the specificity of amplification
were carried out. To control for genomic contaminations, each
sample was amplified without reverse transcriptase or without
DNA. To prove the specificity of PCR fragments, the PCR
product was digested by appropriate restriction enzymes (data
not shown).
Immunoblotting
HepG2 cells and CHO 61/11 cells stably transfected with
recombinant α3-FucT VI were lysed in 1% (w/v) Triton X-100
in PBS. Supernatants were recovered from overnight cultures
in serum-free media and concentrated 10-fold prior to analysis.
Electrophoresis on 10% SDS/PAGE gel and subsequent immu-
noblotting was carried out as described previously (Borsig  et
al., 1998). Nitrocellulose membranes were incubated first with
affinity purified OLI antibodies (1:200) followed by goat anti-
rabbit horse radish peroxidase (1:5000) and stained using the
ECL developing kit according to the manufacturer's instruc-
tions (Amersham, UK).
Fucosyltransferase assay
Cell extracts containing 1% Triton X-100 were prepared as
described previously (Borsig  et al., 1996). Protein concentra-
tions of cell extracts were determined with a BCA protein
assay reagent (Pierce Chemical Co., Rockford, IL). A typical
50 µl reaction mixture contained 40 mM sodium cacodylate
(pH 6.2), 10 mM MnCl2, 10 mM L-fucose, 5 mM ATP, 101
µM GDP-fucose (~5000 c.p.m./nmol, mixture of GDP-[U-14C]
fucose from Amersham and GDP-fucose from Oxford Glyco-
sciences), 5 mM of acceptor substrate (N-acetyllactosamine,
Lacto N-biose I from Sigma, 3'-sialyl-N-acetyllactosamine or
2'-fucosyllactose from Oxford Glycosciences) and 30–60 µg of
protein from cell lysates or 20–30 µl of medium. Controls
without added acceptor were assayed in parallel under the
same conditions. After incubation at 37°C for 2 h the reaction1278
α3FucT VI expression in HepG2 cellsmix was diluted with cold water and applied to a column con-
taining Dowex 1X8-400, formate form (Kukowska-Latallo  et
al., 1990). The flow-through fraction, and 2 ml of a subsequent
water elution, were collected and counted with 1 volume of
Instagel (Packard, IL) in a liquid scintillation counter (Rack-
beta 1219, LKB). In the case of octyl-linked acceptors, assays
were performed essentially as described previously (Palcic  et
al., 1989). After stopping the assay with 1 ml of water, the
assay mixture was loaded on a C18 Sep-Pak cartridge
(Waters), washed three times successively with 5 ml water,
and eluted with 5 ml of methanol.
Metabolic labeling and immunoprecipitation
HepG2 cells were washed with prewarmed PBS before being
starved in methionine-/cysteine-free MEM medium for 20 min
at 37°C. The cells were continuously labeled for 1.5 h with 50
µCi [35S] methionine/cysteine (EXPRE35S35S methionine,
cysteine labeling mix, NEN/ Du Pont, Wilmington/DE) per ml
of met-/cys-free medium or 10 min (pulse/chase) with 100
µCi/ml. Cells were chased for various periods of time with
complete DMEM medium and washed 2 times with ice-cold
PBS. Cells were scraped off the culture dishes in 10 ml ice-
cold PBS containing protease inhibitors per ml: 1 µg antipain,
1 µg aprotinin, 1 µg benzamidine, 0.5 µg leupeptin, 1 µg pep-
statin A, 0.2 mM PMSF), and collected by centrifugation at
1500 × g for 5 min. Cells were homogenized by passing three
times through a 25G5/8 gauge needle in 10 ml PBS containing
1% (w/v) Triton X-100, and lysed for 30 min at 4°C while
rocking. Lysates were cleared by centrifugation for 10 min at
15,000 × g at 4°C and precleared for 1 h at 4°C with 100 µl sus-
pended protein A-Sepharose (Pharmacia) in 10 ml buffer A
(PBS, 1% (w/v) Triton X-100). Immunoprecipitation was car-
ried out essentially as described before (Borsig  et al., 1998).
Controls included preimmune serum and absorption with anti-
gen; in both cases the specific signal was quenched (not
shown). For PNG-ase F and endo-H treatment, 30 µl of 0.5%
SDS, 1% β-mercaptoethanol in water was added to the washed
beads and boiled for 10 min. After cooling, beads were spun
down. The supernatant was adjusted to a final conc. of 1% NP-
40 (w/v) and incubated for 16 h at 37°C either with 500 U of
PNG-ase F (NEB, Beverly/MA) or with 50 U of endo-H
(NEB). For neuraminidase treatment, to the washed beads
30 µl of 50 mM sodium citrate, pH 4.5, protease inhibitors (see
above) and 50 U of neuraminidase (NEB) were added and
incubated for 16 h at 37°C. The reaction was stopped by adding
an equal volume of 2× SDS–PAGE sample buffer and boiled
for 5 min. Immunoprecipitated proteins were separated by
SDS–PAGE on a 10% acrylamide gel. After electrophoresis,
gels were soaked in 50% methanol/10% acetic acid, dried, and
exposed to FUJI x-ray films.
Confocal laser scanning double immunofluorescence 
microscopy
HepG2 cells were fixed and permeabilized as described previ-
ously (Borsig  et al., 1996). The first antibodies were affinity
purified rabbit antibodies to α3-FucT VI (OLI) raised to solu-
ble recombinant α3-FucT VI (Borsig  et al., 1998) or mono-
clonal antibody mAB2/36/118 to human β1,4-
galactosyltransferase (Berger  et al., 1986), respectively. A
rabbit polyclonal antiserum to TGN46, the human homologue
of rat TGN38 was obtained from α3-FucT V. Ponnambalam
(Dundee) Preimmune serum in an appropriate dilution was
used. In case of preabsorption of OLI antibodies, affinity puri-
fied antibodies were preincubated with 10 µg of antigen for 1 h
prior to the staining procedure. Fluorescein isothiocyanate
(FITC) and Texas red (TR)-conjugated secondary antibodies
were obtained from Dako (anti-mouse Ig) and Organon (anti
rabbit Ig). For mounting of coverslips embedding medium was
used as described previously (Borsig  et al., 1996). Immuno-
fluorescence images were taken on a Leica microscope using
dual fluorescence mode for Texas red and FITC. Single fluo-
rescence images or extended focus projections were generated
using the Imaris software (Bitplane, Zürich Switzerland).
Incubation of cells with monensin
Monolayers were incubated for the indicated times in complete
medium to which a stock solution of monensin (Calbiochem)
in ethanol (1 mg/ml) was added to a final concentration of
2 µM monensin (1,4 µl/ml medium); controls were supple-
mented with the same volume of ethanol. Recovery from mon-
ensin treatment was carried out by replacing the monensin-
supplemented medium by normal medium.
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